ImmunityBio reported early trial data showing its off‑the‑shelf allogeneic CD19 CAR‑NK therapy, given with rituximab, produced durable complete responses in Waldenström’s macroglobulinemia patients without chemotherapy lymphodepletion. The readout covers patients enrolled in the early‑stage study and highlights a potentially gentler, outpatient‑friendly cell therapy regimen. The combination’s responses suggest CAR‑NK platforms can be active against B‑cell malignancies while avoiding toxic conditioning. Sponsors will need to expand cohorts, present durability and safety data, and define a regulatory path that accounts for the allogeneic product’s manufacturing and scalability advantages.